{"url_path":"/sec/cik-0001012477/8-k/2026-02-12/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-12","source_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-013880-index.html","accession_number":"0001104659-26-013880","cik":"0001012477","ticker":null,"issuer_name":"AVADEL PHARMACEUTICALS PLC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-013880-index.html","primary_entity_key":"0001012477","primary_entity_name":"AVADEL PHARMACEUTICALS PLC"},"word_count":137,"has_tables":true,"body_markdown":"**Item 1.02**\n**Termination of a Material Definitive Agreement.**\n\n \n\nEffective as of February 12, 2026, in connection with the Acquisition\n(as defined below), Avadel Pharmaceuticals plc (“Avadel” or the “Company”) exercised its right to terminate the\nOpen Market Sale AgreementSM , dated May 8, 2024, by and between Avadel and Jefferies LLC, with respect to an “at-the-market”\noffering program under which the Company could sell, from time to time, its ordinary shares.\n\n \n\nOn February 12, 2026, in connection with the Acquisition, Avadel\nexercised its option to prepay RTW Royalty II DAC (“RTW”) approximately $60,246,950 to terminate existing royalty payments and obligations\npursuant to the Purchase and Sale Agreement, dated March 29, 2023, by and between Avadel, Avadel CNS Pharmaceuticals, LLC and RTW\n(the “Royalty Purchase Agreement”). The Royalty Purchase Agreement will automatically terminate upon receipt of such payments."}